Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
TMB-H + PD-L1 negative
i
Other names:
TMB | Tumor Mutational Burden, PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
29126
Related biomarkers:
Expression
Mutation
CNA
Others
‹
NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)
PD-L1 rs1411262 (1)
PD-L1 rs2297136 (1)
PD-L1 rs4143815 (1)
PD-L1 rs822339 (1)
PD-L1 T290M (0)
PD-L1 mutation (0)
NF1 L581Ffs*6 + KRAS A146P + NRAS Q61K + TP53 R175H + PD-L1 T290M (1)
PD-L1 rs1411262 (1)
PD-L1 rs2297136 (1)
PD-L1 rs4143815 (1)
PD-L1 rs822339 (1)
PD-L1 T290M (0)
PD-L1 mutation (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
TMB-H + PD-L1 negative
Melanoma
TMB-H + PD-L1 negative
Melanoma
atezolizumab + vemurafenib + cobimetinib
Sensitive: B - Late Trials
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
B
atezolizumab + vemurafenib + cobimetinib
Sensitive: B - Late Trials
atezolizumab + vemurafenib + cobimetinib
Sensitive
:
B
TMB-H + PD-L1 negative
Urothelial Cancer
TMB-H + PD-L1 negative
Urothelial Cancer
tislelizumab-jsgr
Sensitive: C4 – Case Studies
tislelizumab-jsgr
Sensitive
:
C4
tislelizumab-jsgr
Sensitive: C4 – Case Studies
tislelizumab-jsgr
Sensitive
:
C4
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login